Revised Schedule M guidelines for Indian pharma GMP compliance
India's revised Schedule M guidelines set binding pharma GMP rules. Review quality systems, validation, computerised systems and the CDSCO PDF.
Revised Schedule M guidelines for Indian pharmaceutical manufacturers
India's revised Schedule M guidelines set binding good manufacturing practice requirements for pharmaceutical products under the Drugs Rules, 1945. They require documented quality systems, quality risk management, controlled manufacturing and batch release, continuing qualification and validation, and validated GMP-related computerised systems, along with rules for premises, plant and equipment. G.S.R. 922(E), dated 28 December 2023, notified the revision. CDSCO lists that notification in its official Gazette index.
Schedule M's heading refers to rules 71, 74, 76 and 78. That heading is on page 544 of the September 2024 Drugs Rules compilation. Part I, on page 545, sets out the main GMP principles for pharmaceutical products.
What the revised Schedule M guidelines require
Start with who approved the work, what evidence supports it and what happened after a failure. The points below are a starting point. Product-specific parts of Schedule M still need their own check.
A documented and resourced quality system
GMP applies across manufacture, technology transfer and commercial manufacturing through product discontinuation. Paragraphs 1.4 and 1.5 require competent personnel, suitable premises, equipment and facilities, and written production and quality-control operations. They also cover defined managerial responsibilities, supplier controls, in-process controls, calibration and validation. See Schedule M, pages 546-547.
A quality manual, or equivalent documentation, must describe the quality management system and management responsibilities. Management reviews must involve senior management and take place at least annually, unless otherwise justified. If the review schedule differs, document the justification. The relevant provisions are paragraphs 1.6-1.7, page 548.
Risk management, deviations and product quality review
Schedule M expressly requires a quality risk management system. Deviations, suspected product defects and other problems must be reported, investigated and recorded. Appropriate root-cause analysis and corrective and preventive action, or CAPA, must follow. The manufacturer must also monitor CAPA effectiveness. Check whether the action worked. Closing the record is a separate step. See paragraph 1.5 and its continuation, pages 547-548.
Product quality review inputs include failed batches, significant deviations, changes to processes or analytical methods, stability trends, and quality-related returns, complaints and recalls. The review also covers equipment and utility qualification and technical agreements. For a gap review, check whether these records can be evaluated together. These are selected inputs from page 549, not an exhaustive list.
Continuing qualification and validation
Qualification and validation are not one-off exercises. Paragraphs 5.3-5.12 require an ongoing programme after the first implementation, based on periodic review. Significant changes that may affect product quality must be qualified and validated. Responsibilities, approved protocols, written results and conclusions must be documented. Analytical methods, automated systems and cleaning procedures get particular attention in Schedule M, page 552.
The same provisions require documentary evidence for design, installation and operational qualification. They also cover process validation, also called performance qualification. When you review a change, look at the original qualification evidence and at the assessment of the changed condition.
Batch release and computerised systems
Batch release requires authorised-person certification that production and control meet the licence and applicable regulations. QC records must be reviewed before release. Specification failures require investigation, which can extend to related batches and products. These obligations appear in paragraphs 1.5 and 19.8.1.
GMP-related computerised systems must be validated. The depth and scope depend on the system's diversity, complexity and criticality. Installation and operational qualification demonstrate hardware and software suitability. Qualified commercial software does not require the same level of testing. Buying a commercial package is not, by itself, an exemption. See sections 20.1-20.3.
A practical manufacturer's gap review
Use the table as an internal review aid drawn from the requirements above. CDSCO does not prescribe this table, and the table does not certify a plant.
| Area | Evidence to examine |
|---|---|
| Quality management | Quality manual, assigned responsibilities and management-review records |
| Deviations and changes | Investigations, root-cause analysis, change approvals and CAPA effectiveness checks |
| Validation | Approved protocols, results, conclusions and periodic-review evidence |
| Batch release | QC-record review, failure investigations and authorised-person certification |
| Computerised systems | Validation scope and qualification evidence suited to the system |
Trace one completed deviation and one manufacturing change through their records. Check whether the records show the decision, its approval and the follow-up. That is a practical way to test the documented investigation, change-evaluation and CAPA duties in paragraph 1.5, pages 547-548.
Include outsourced work. Paragraph 9.5 requires a written contract between the loan licensee or contract giver and the manufacturing facility provider or contract acceptor. The contract must allocate responsibilities, including communication, technical arrangements and the authorised person's batch-release duties. Relevant manufacturing, analytical and distribution records, plus reference samples, must be available to the contract giver. See page 558.
Check complaint handling against actual records. Written procedures, a responsible person, records and investigation are required for potentially defective products. Consider whether other batches are affected and whether recall is needed. Record decisions against the batch records. Serious quality problems trigger information to the licensing authorities. Paragraph 6.11 also requires a pharmacovigilance system for collecting, processing and forwarding adverse-reaction reports to the licensing authorities. These duties appear on page 553.
Review self-inspection follow-up too. Paragraphs 10.1-10.2 require documented procedures to assess production and QC, detect shortcomings and recommend corrective action. Check what happened after findings were recorded. Effective follow-up is required under paragraphs 10.1-10.2, page 559.
Keep sample retention separate from document retention in this review. Paragraph 19.8.2 requires finished-product retention samples for at least one year after expiry. Active starting-material samples must remain for at least one year beyond the corresponding finished product's expiry. Other starting materials have a minimum two-year period if stability permits, excluding solvents, gases and water. These are sample-retention requirements, not a universal period for keeping all GMP documents.
For each gap, record the requirement, the available evidence and the work still needed. Assign an owner and review completion against the underlying provision. A missing procedure and a procedure that staff do not follow need different corrective work. It's a suggested review method, not an extra filing under Schedule M.
Where to find the official Schedule M GMP PDF
Start with the CDSCO September 2024 Drugs Rules PDF. Schedule M begins on page 544. Use that PDF for the cGMP guidelines according to Schedule M, and check each item against the provision it cites.
But the compilation date matters.
Read it alongside later instruments listed in CDSCO's Gazette index:
- G.S.R. 922(E), dated 28 December 2023, is the original revised Schedule M notification.
- G.S.R. 666(E), dated 25 October 2024, is its corrigendum.
- G.S.R. 10(E), dated 4 January 2025, is indexed as a Schedule M extension notification.
- G.S.R. 11(E) is indexed as a corrigendum to G.S.R. 10(E). The index entry begins 2025.01.06, while the release-date column says 4 January 2025. Read the notification before you rely on either date.
- G.S.R. 127(E), dated 11 February 2025, concerns extension of the implementation timeline.
The September 2024 compilation cannot incorporate those later instruments. Check the Gazette index again before you treat this list as current. For deadline or eligibility decisions, read the February 2025 extension notification with the original notification and any later instrument that applies. Do not treat these extension notices as an open application window.
CDSCO's circular index lists a 3 June 2026 circular on implementing Schedule M's pharmacovigilance requirement. The implementation circular says officers may verify compliance during routine inspections and other regulatory activities. It is not a deadline extension.
RegAffairs AI's answer on India's revised Schedule M collects the cited sources for this question. For a plant-level assessment, match the products and processes to the relevant specific provisions, alongside the main GMP principles in Schedule M.